NIKA Pharmaceuticals Narrows Losses Amidst Zero Revenue, Going Concern Doubts Persist

TL;DR

**NIKA is a speculative bet on a pre-revenue pharma company with a massive accumulated deficit and a going concern warning; avoid until they show actual sales.**

AI Summary

NIKA PHARMACEUTICALS, INC. reported a net loss of $18,381 for the three months ended June 30, 2025, an improvement from the $22,457 net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $31,327, significantly lower than the $65,342 loss in the prior year. The company generated no revenue in either period. Total operating expenses decreased to $18,381 for the three months ended June 30, 2025, from $22,457 in 2024, primarily due to a reduction in professional fees from $14,957 to $4,081. Cash increased substantially to $15,616 as of June 30, 2025, from $2,083 at December 31, 2024, driven by $45,000 in loans from related parties. The company's accumulated deficit grew to $8,958,938 as of June 30, 2025, and it continues to operate without revenue, raising substantial doubt about its ability to continue as a going concern. Strategic developments include increasing its controlling interest in Nika Europe, Ltd. to 99.99% and uplisting its common stock to OTCQB.

Why It Matters

NIKA's continued lack of revenue and substantial accumulated deficit of $8,958,938 as of June 30, 2025, signals extreme risk for investors, despite reduced net losses. The company's reliance on related-party loans, totaling $284,164 due to related parties, for operational funding is unsustainable and highlights a critical liquidity issue. For employees and customers, the 'going concern' warning indicates significant instability and potential disruption. In the competitive pharmaceutical market, NIKA's inability to generate revenue from its 'Exclusive Rights Agreement' for Thymus Nuclear Glycoprotein (TNG) or its 99.99% stake in Nika Europe, Ltd. suggests a failure to commercialize its assets, leaving it far behind established players.

Risk Assessment

Risk Level: high — The company has an accumulated deficit of $8,958,938 as of June 30, 2025, and has generated no revenue to date, explicitly stating these factors 'raise substantial doubt about its ability to continue as a going concern.' Furthermore, NIKA relies heavily on related-party loans, with $284,164 due to related parties as of June 30, 2025, indicating a lack of independent funding sources.

Analyst Insight

Investors should exercise extreme caution and avoid NIKA stock until the company demonstrates a clear path to revenue generation and profitability. The 'going concern' warning and reliance on related-party financing suggest significant financial instability. Monitor for concrete progress on commercializing TNG or other pharmaceutical products.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$31,607

total Debt

$284,164

net Income

-$18,381

eps

$0.00

gross Margin

N/A

cash Position

$15,616

revenue Growth

N/A

Key Numbers

• $18,381 — Net Loss (Q2 2025) (Decreased from $22,457 in Q2 2024)
• $31,327 — Net Loss (YTD Q2 2025) (Decreased from $65,342 in YTD Q2 2024)
• $0 — Revenue (No revenue generated for Q2 2025 or Q2 2024)
• $8,958,938 — Accumulated Deficit (As of June 30, 2025, indicating significant historical losses)
• $15,616 — Cash (As of June 30, 2025, up from $2,083 at December 31, 2024)
• $284,164 — Due to related parties (Total current liabilities as of June 30, 2025, primarily from related-party loans)
• 1,026,406,001 — Common Shares Outstanding (As of August 7, 2025)
• 99.99% — Controlling Interest (NIKA's stake in Nika Europe, Ltd. as of May 16, 2024)
• $45,000 — Loans from related parties (Cash provided by financing activities for the six months ended June 30, 2025)

Key Players & Entities

• NIKA PHARMACEUTICALS, INC. (company) — registrant
• Dimitar Slavchev Savov (person) — CEO, CFO, President, Director, and owner of 70% stake in VITAL
• Nika Europe, Ltd. (company) — 99.99% controlled subsidiary
• VITAL FE Joint Stock Company (company) — partner for Exclusive Rights Agreement for TNG
• Thymus Nuclear Glycoprotein (TNG) (other) — pharmaceutical product with exclusive rights
• Phil E. Ray (person) — former Director, President and Chief Executive Officer
• A. Terry Ray (person) — former Director and Secretary
• Clifford Redekop (person) — Director and Secretary
• Nika BioTechnology, Inc. (company) — merged into NIKA PHARMACEUTICALS, INC.
• Nika Pharmaceuticals, Ltd. (company) — wholly-owned and managed by CEO Dimitar Slavchev Savov

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: NIKA PHARMACEUTICALS, INC. continues to operate with no revenue and has an accumulated deficit of $8,958,938 as of June 30, 2025. This persistent lack of revenue and significant historical losses raise substantial doubt about the company's ability to continue as a going concern.
• Dependence on Related Party Financing [high — financial]: The company's cash position increased to $15,616 as of June 30, 2025, primarily due to $45,000 in loans from related parties. This reliance on related party financing for liquidity, coupled with no revenue generation, presents a significant financial risk.
• Lack of Revenue Generation [high — operational]: NIKA PHARMACEUTICALS, INC. generated no revenue in the three and six months ended June 30, 2025, nor in the comparable periods of 2024. This complete absence of revenue is a critical operational and financial challenge.
• Uplisting to OTCQB [medium — regulatory]: The company's common stock has been uplisted to OTCQB. While this may increase visibility, it also subjects the company to the reporting and compliance requirements of this exchange, which could pose regulatory challenges.
• Concentration in Nika Europe, Ltd. [medium — operational]: NIKA has increased its controlling interest in Nika Europe, Ltd. to 99.99%. While this indicates a strategic focus, it also means the company's performance is heavily tied to the success of this single subsidiary.

Industry Context

The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on substantial funding to bring products to market. NIKA PHARMACEUTICALS, INC. operates within this challenging landscape, currently showing no revenue and significant accumulated losses, indicating it is in a very early, pre-commercialization stage or facing severe operational difficulties.

Regulatory Implications

The uplisting to OTCQB means NIKA must adhere to the exchange's disclosure and compliance standards. Failure to meet these requirements could lead to delisting. Furthermore, as a pharmaceutical company, it is subject to stringent regulations from bodies like the FDA, although specific product development details are not provided in this filing.

What Investors Should Do

1. Monitor related party loan activity
2. Scrutinize future revenue generation plans
3. Assess the impact of Nika Europe, Ltd. performance
4. Evaluate the going concern disclosure

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q, showing a net loss of $18,381 and cash of $15,616, with significant related party debt.
• 2024-12-31: End of Fiscal Year 2024 — Previous reporting period, showing cash of $2,083 and a substantial accumulated deficit.
• 2024-05-16: Increased Controlling Interest in Nika Europe, Ltd. — NIKA increased its stake to 99.99%, indicating a strategic consolidation of its European operations.
• 2025-08-07: Common Shares Outstanding Date — As of this date, there were 1,026,406,001 common shares outstanding, relevant for per-share calculations.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (NIKA's accumulated deficit of $8,958,938 highlights its long-term unprofitability and raises going concern issues.)

Due to related parties

Amounts owed by the company to individuals or entities that have a close relationship with the company, such as officers, directors, or other affiliated companies. (NIKA has $284,164 due to related parties as of June 30, 2025, primarily from loans, indicating reliance on internal financing.)

Going concern

The assumption that a company will continue to operate for the foreseeable future. If there is substantial doubt about a company's ability to continue as a going concern, it must be disclosed. (The company's lack of revenue and significant losses lead to substantial doubt about its ability to continue as a going concern.)

Uplisting

The process of moving a company's stock from a lower-tier exchange or quotation service to a higher-tier one, such as moving from OTC Pink to OTCQB. (NIKA's uplisting to OTCQB is a strategic move that may affect its visibility and regulatory obligations.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, NIKA PHARMACEUTICALS, INC. has significantly reduced its net loss from $65,342 to $31,327, primarily driven by a substantial decrease in professional fees from $52,457 to $15,226. Total assets have increased from $17,934 to $31,607, largely due to a rise in cash from $2,083 to $15,616, funded by related party loans. However, the company continues to generate no revenue, and its accumulated deficit has grown to $8,958,938, underscoring persistent financial challenges.

Key Financial Figures

• $0.0001 — The number of shares of Common Stock, $0.0001 par value of the registrant outstanding
• $8,958,938 — e Company has an accumulated deficit of $8,958,938 as of June 30, 2025 and has generated n
• $0 — equivalent common shares were valued at $0.0003, the last sale price for common sh
• $2,400,000 — volume), for total non-cash expense of $2,400,000. On April 7, 2022, the Company signed

Filing Documents

• form-10q.htm (10-Q) — 367KB
• exhibit31-1.htm (EX-31.1) — 7KB
• exhibit32-1.htm (EX-32.1) — 3KB
• 0001826466-25-000087.txt ( ) — 2029KB
• nika-20250630.xsd (EX-101.SCH) — 17KB
• nika-20250630_cal.xml (EX-101.CAL) — 22KB
• nika-20250630_def.xml (EX-101.DEF) — 70KB
• nika-20250630_lab.xml (EX-101.LAB) — 150KB
• nika-20250630_pre.xml (EX-101.PRE) — 133KB
• form-10q_htm.xml (XML) — 185KB

Financial

Item 1. Financial 3 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 (Unaudited) 3 Condensed Consolidated Statements of Operations for the three months Ended June 30, 2025 and 2024 (Unaudited) 4 Condensed Consolidated Statements of Stockholders Deficit for the three months Ended June 30, 2025 and 2024 (Unaudited) 5 Condensed Consolidated Statements of Cash Flows for the three months Ended June 30, 2025 and 2024 (Unaudited) 6 Notes to Unaudited Condensed Consolidated Financial Statements 7

Managements Discussion and

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations 13

Quantitative and

Item 3. Quantitative and Qualitative Disclosures About Market Risks. 16

Controls and Procedures

Item 4. Controls and Procedures 16 PART II. 17

Legal Proceedings

Item 1. Legal Proceedings. 17 .

Risk Factors

Item 1A. Risk Factors . 17

Unregistered Sales of

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 17

Defaults Upon Senior

Item 3. Defaults Upon Senior Securities. 17

Mine Safety Disclosures

Item 4. Mine Safety Disclosures. 17

Other Information

Item 5. Other Information. 17

Exhibits

Item 6. Exhibits. 17 EXHIBIT INDEX 17

Consolidated Financial Statements

Item 1. Consolidated Financial Statements NIKA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2025 December 31, 2024 ASSETS (Unaudited) (Audited) Current Assets: Cash $ 15,616 $ 2,083 Prepaid expenses 15,991 15,851 Total current assets 31,607 17,934 Total assets: $ 31,607 $ 17,934 LIABILITIES AND STOCKHOLDERS DEFICIT Current Liabilities: Due to related parties $ 284,164 $ 239,164 Total Current Liabilities $ 284,164 $ 239,164 Total Liabilities $ 284,164 $ 239,164 Commitments and contingencies Stockholders' Deficit: Preferred Stock; par value $ 0.0001 ; 15,000,000 shares authorized; 15,000,000 and 10,000,000 shares issued and outstanding, respectively 1,500 1,500 Common Stock; par value $ 0.0001 ; 2,700,000,000 shares authorized; 1,026,406,001 and 876,090,000 shares issued and outstanding, respectively 102,641 102,168 Additional paid-in capital 8,602,240 8,602,714 Accumulated other comprehensive income Accumulated deficit ( 8,958,938 ) ( 8,927,612 ) Total Stockholders' Deficit ( 252,557 ) ( 221,230 ) Total Liabilities and Stockholders' Deficit $ 31,607 $ 17,934 The accompanying notes are an integral part of these unaudited consolidated financial statements. 3 NIKA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED (Unaudited) For the Three Months Ended For the Six Months Ended June 30, June 30, 2025 2024 2025 2024 Revenue $ $ $ $ Operating Expenses: General and administrative $ 14,300 $ 7,500 $ 16,101 $ 12,885 Professional fees 4,081 14,957 15,226 52,457 Total operating expenses 18,381 22,457 31,327 65,342 Loss from operations ( 18,381 ) ( 22,457 ) ( 31,327 ) ( 65,342 ) Loss before provision for income taxes ( 18,381 ) ( 22,457 ) ( 31,327 ) ( 65,342 ) Provision for income taxes Net Loss $ ( 18,381 ) $ ( 22,457 ) $ (

financial statements reflect all adjustments, consisting of only normal

financial statements reflect all adjustments, consisting of only normal recurring items, which, in the opinion of management, are necessary for a fair necessarily indicative of the results to be expected for the full year ending December 31, 2024. These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes included in the Companys Annual Report on Form 10-K for the year ended December 31, 2024. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial reporting period. Actual results may differ from those estimates. Concentrations of Credit Risk We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash. Reclassifications Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the financial Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. As of June 30, 2025 and December 31, 2024, the Company had no cash equivalents. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Centennial Ventures, Inc. There h

View Full Filing

View this 10-Q filing on SEC EDGAR